1005201-16-0

Basic information

• Product Name: 2-[3-(4-fluorophenyl)-1-benzofuran-5-yl]-5-methyl-1,3,4-oxadiazole
• Synonyms: 2-[3-(4-fluorophenyl)-1-benzofuran-5-yl]-5-methyl-1,3,4-oxadiazole
• CAS NO: 1005201-16-0
• Molecular Weight: 294.285
• Mol File: 1005201-16-0.mol

Chemical Properties

• CAS DataBase Reference: 2-[3-(4-fluorophenyl)-1-benzofuran-5-yl]-5-methyl-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-(4-fluorophenyl)-1-benzofuran-5-yl]-5-methyl-1,3,4-oxadiazole(1005201-16-0)
• EPA Substance Registry System: 2-[3-(4-fluorophenyl)-1-benzofuran-5-yl]-5-methyl-1,3,4-oxadiazole(1005201-16-0)

Safety Data

• Hazardous Substances Data: 1005201-16-0(Hazardous Substances Data)

Upstream product

• 1005205-64-0 2-(3-bromo-1-benzofuran-5-yl)-5-methyl-1,3,4-oxadiazole 
• 1765-93-1 4-fluoroboronic acid 

Relevant articles and documents

GSK-3BETAINHIBITOR

For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain permeability

Glycogen synthase kinase 3β (GSK-3β) inhibition is expected to be a promising therapeutic approach for treating Alzheimer's disease. Previously we reported a series of 1,3,4-oxadiazole derivatives as potent and highly selective GSK-3β inhibitors, however,